Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non‐small cell lung cancer or colorectal cancer: a randomized, double‐blind, placebo‐controlled, international multicentre phase II study (the ACT‐ONE trial)

Abstract

Background Cancer cachexia is a major cause of morbidity and mortality with no widely approved treatment. Methods The ACT‐ONE trial is a randomized, double‐blind, parallel group, placebo‐controlled, phase II multicentre trial in patients (25‐80 years) with stages III or IV colorectal cancer or non‐small cell lung cancer‐related cachexia that tested two doses of espindolol (a novel non‐selective β blocker with central 5‐HT1a and partial β2 receptor agonist effects). The primary endpoint was the difference in the rate of weight change over 16 weeks (linear mixed‐effect model for repeated measures) between high‐dose espindolol and placebo. Results Eighty‐seven patients were randomized centrally in blocks in a ratio 3:2:1 [42 high dose, 10 mg twice daily (bd):31 placebo:14 low dose, 2.5 mg bd]. High‐dose espindolol produced a statistically and clinically significant weight gain (+0.54 kg/4 weeks, 95% CI 0.38–0.70) compared with a weight loss on placebo (−0.21 kg/4 weeks, 95% CI ‐0.37–0.05); P < 0.0001. High‐dose espindolol produced a statistically significant increase in lean body mass, whilst changes in fat mass were neutral. Hand grip strength significantly (high dose −1.15 ± 0.7 kg, placebo −3.51 ± 0.8 kg change per 4 weeks; P = 0.0134), stair climbing power, and 6‐min walk test non‐significantly were all directionally in favour of high‐dose espindolol. There were no clinically significant differences in safety signals or survival between treatment groups, although a numerical excess of dyspnoea was seen with high‐dose espindolol (19.1%) compared with placebo (3.2%). Conclusions This positive trial showed that espindolol 10 mg bd significantly reversed weight loss, improved fat free mass, and maintained fat mass in advanced colorectal cancer and non‐small cell lung cancer‐related cachexia. This was associated with a significant improvement in handgrip strength, supporting the further investigation of 10 mg bd espindolol for the treatment of cancer cachexia. Although not powered to look at dose response, most treatment effects for low dose lay between high dose and placebo, suggesting that there may be a dose response in the effects of espindolol.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 28

1. 1.

   Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, et al Cachexia: a new definition. Clin Nutr 2008;27:793–799.

   Not in our library10.1016/j.clnu.2008.06.013

2. 2.

   Argilés JM, Busquets S, Stemmler B, López‐Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer 2014;14:754–762.

   Not in our library10.1038/nrc3829

3. 3.

   Frishman WH. Pindolol: a new β‐adrenoceptor antagonists with partial agonist activity. N Engl J Med 1983;308:940–944.

   Not in our library10.1056/nejm198304213081606

4. 4.

   Pleadin J, Vulić A, Perši N. β‐adrenergic agonists: substances with anabolic effect in animals for meat production. MESO: prvi hrvatski časopis o mesu 2012;14:80–87.

   Not in our library

5. 5.

   Palm D, Lang K, Niggemann B, Drell TL, Kai Masur K, Zaenker KS, et al The norepinephrine‐driven metastasis development of PC‐3 human prostate cancer cells in BALB/c nude mice is inhibited by β‐blockers. Int J Cancer 2006;118:2744–2749.

   Not in our library10.1002/ijc.21723

6. 6.

   Kung T, Springer J, Doehner W, Anker SD, von Haehling S. Novel treatment approaches to cachexia and sarcopenia: highlights from the 5th Cachexia Conference. Expert Opin Investig Drugs 2010;4:579–585.

   Not in our library10.1517/13543781003724690

7. 7.

   Pötsch MS, Tschirner A, Palus S, von Haehling S, Doehner W, Beadle J, et al The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats. J Cachexia Sarcopenia Muscle 2014;5:149–158.

   Not in our library10.1007/s13539-013-0125-7

8. 8.

   Quigley EM, Devane J, Young D, Butler J. A randomised, controlled, double‐blind trial of s‐pindolol in irritable bowel syndrome (IBS). Am J Gastroenterol 2007;102:S501.

   Not in our library

9. 9.

   Stewart Coats AJ, Srinivasan V, Surendran J, Chiramana H, Vangipuram SR, Bhatt NN, et al The ACT‐ONE trial, a multicentre, randomised, double‐blind, placebo‐controlled, dose‐finding study of the anabolic/catabolic transforming agent, MT‐102 in subjects with cachexia related to stage III and IV non‐small cell lung cancer and colorectal cancer: study design. J Cachexia Sarcopenia Muscle 2011;2:201–207.

   Not in our library10.1007/s13539-011-0046-2

10. 10.

    Bassey Hand grip strength test NIH, 1990.

    Not in our library

11. 11.

    Bean JF, Kiely DK, LaRose S, Alian J, Frontera WR. Is stair climb power a clinically relevant measure of leg power impairments in at‐risk older adults? Arch Phys Med Rehabil 2007;88:604–649.

    Not in our library10.1016/j.apmr.2007.02.004

12. 12.

    Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al A short physical performance battery assessing lower extremity function: association with self‐reported disability and prediction of mortality and nursing home admission. J Gerontol 1994;49:M85–M94.

    Not in our library10.1093/geronj/49.2.m85

13. 13.

    Enright PL. The six‐minute walk test. Respir Care 2003;48:783–785.

    Not in our library

14. 14.

    Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–655.

    Not in our library

15. 15.

    Dobs AS, Boccia RV, Croot CC, Gabrail NY, Dalton JT, Hancock ML, et al Effects of enobosgroup on muscle wasting and physical function in patients with cancer: a double‐blind, randomised controlled phase 2 trial. Lancet Oncol 2013;14:335–345.

    Not in our library10.1016/s1470-2045(13)70055-x

16. 16.

    Crawford JC, Johnston MA, Hancock ML, Small SG, Taylor RP, Dalton JP, et al Enobosarm, a selective androgen receptor modulator (SARM) increases lean body mass (LBM) in advanced NSCLC patients; updated results of two pivotal, international Phase 3 trials. Presented at the MASCC/ISOO International Symposium on Supportive Care in Cancer. Miami, FL. June 26‐28, 2014. Abstract MASCC‐0546. (Abstract)

    Not in our library

17. 17.

    Garcia JM, Friend J, Allen S. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer‐related cachexia: a multicenter, randomised, double‐blind, crossover, pilot study. Support Care Cancer 2013;21:129–137.

    Not in our library10.1007/s00520-012-1500-1

18. 18.

    Garcia JM, Boccia RV, Graham CD, Yan Y, Duus EM, Allen S, et al Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo‐controlled, double‐blind trials. Lancet Oncol 2015;16:108–116.

    Not in our library10.1016/s1470-2045(14)71154-4

19. 19.

    Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, et al Anamorelin in patients with non‐small‐cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double‐blind, phase 3 trials. Lancet Oncol 2016. pii: S1470‐2045(15)00558‐6.;doi:10.1016/S1470-2045(15)00558-6.

    Not in our library10.1016/s1470-2045(15)00558-6

20. 20.

    Kraft M, Kraft K, Gärtner S, Mayerle J, Simon P, Weber E, et al L‐Carnitine‐supplementation in advanced pancreatic cancer (CARPAN)—a randomised multicentre trial. Nutr J 2012;11:52.

    Not in our library10.1186/1475-2891-11-52

21. 21.

    Yeh KY, Wang HM, Chang JW, Huang JS, Lai CH, Lan YJ, et al Omega‐3 fatty acid‐, micronutrient‐, and probiotic‐enriched nutrition helps body weight stabilization in head and neck cancer cachexia. Oral Surg Oral Med Oral Pathol Oral Radiol 2013;116:41–48.

    Not in our library10.1016/j.oooo.2013.01.015

22. 22.

    Del Fabbro E, Dev R, Hui D, Palmer L, Bruera E. Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double‐blind placebo‐controlled trial. J Clin Oncol 2013;31:1271–1276.

    Not in our library10.1200/jco.2012.43.6766

23. 23.

    Wiedenmann B, Malfertheiner P, Friess H, Ritch P, Arseneau J, Mantovani G, et al A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol 2008;6:18–25.

    Not in our library

24. 24.

    Wu C, Fernandez SA, Criswell T, Chidiac TA, Guttridge D, Villalona‐Calero M, et al Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease. Pancreas 2013;42:813–818.

    Not in our library10.1097/mpa.0b013e318279b87f

25. 25.

    Yennurajalingam S, Willey JS, Palmer JL, Allo J, Del Fabbro E, Cohen EN, et al The role of thalidomide and placebo for the treatment of cancer‐related anorexia‐cachexia symptoms: results of a double‐blind placebo‐controlled randomised study. J Palliat Med 2012;15:1059–1064.

    Not in our library10.1089/jpm.2012.0146

26. 26.

    http://www.biotech‐intelligence.com/html/html/2a462148882a297c8eafbeafbaeff7ff.html.

    Not in our library

27. 27.

    Lainscak M, Keber I, Anker SD. Body composition changes in patients with systolic heart failure treated with beta‐blockers: a pilot study. Int J Cardiol 2006;106:319–322.

    Not in our library10.1016/j.ijcard.2005.01.061

28. 28.

    von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle 2015;4:315–316.

    Not in our library10.1007/s13539-010-0003-5

Cited by papers we hold 2

• Cancer cachexia: molecular mechanisms and treatment strategies · 2023
  No notice
• The evolution of body composition in oncology—epidemiology, clinical trials, and the future of patient care: facts and numbers · 2018
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.